Scan for PSMA I PLUVICTO I HCP

Why Scan for PSMA?

Scanning to Determine Status

Patients in Your Practice

Why Scan for PSMA?

More than 80% of patients with prostate cancer are PSMA+, making PSMA an ideal diagnostic and therapeutic target^1-5

PSMA is a transmembrane protein that is overexpressed on prostate cancer cells⁶
PSMA+ lesions can be visualized using PSMA positron emission tomography (PET)^7,8
Knowing your patient is PSMA+ may enable you to offer PLUVICTO, a PSMA-targeted radioligand therapy (RLT)^7-9

CT, computed tomography; PSMA, prostate specific membrane antigen; PSMA+, PSMA positive.

Scanning to Determine PSMA Status

PSMA scanning helps you see and target PSMA+ mCRPC^7-9

PSMA PET demonstrates high sensitivity and specificity to see PSMA+ metastases^7-10
Once a scan confirms PSMA+ mCRPC, the disease* can be treated with PLUVICTO wherever it has spread—bone, nodal, and visceral metastases^7,9,11

>80% of men with prostate cancer are PSMA+, making PSMA an ideal diagnostic and therapeutic target.^1-5

*Please see full indication for further details.

Scan to determine PSMA status. Knowing your patient who has received an ARPI and taxane is PSMA+ enables you to offer a PSMA-targeted RLT.⁶

ARPI, androgen receptor pathway inhibitor; mCRPC, metastatic castration-resistant prostate cancer.

Patients in Your Practice Who May Benefit From PLUVICTO

Consider a PSMA PET/CT for patients in your practice with mCRPC^6,12

ADT, androgen deprivation therapy; ECOG PS, Eastern Cooperative Oncology Group performance status; mHSPC, metastatic hormone-sensitive prostate cancer; OS, overall survival; PSA, prostate-specific antigen.

^aProduct used as directed by product Prescribing Information/label.

What is your next step for patients like Stan?

BCR, biochemical recurrence; nmCRPC, nonmetastatic castration-resistant prostate cancer; PC, prostate cancer; PSADT, prostate-specific antigen doubling time.

^a Product used as directed by product Prescribing Information/label.

What is your next step for patients like Maurice?

What is your next step for patients like José?

What is your next step for patients like Elliot?

See how PLUVICTO helped patients like this in the VISION trial

View OS Data

References:
1. Hupe MC, Philippi C, Roth D, et al. Expression of prostate-specific membrane antigen (PSMA) on biopsies is an independent risk stratifier of prostate cancer patients at time of initial diagnosis. Front Oncol. 2018;8:623. doi:10.3389/fonc.2018.00623 2. Pomykala KL, Czernin J, Grogan TR, Armstrong WR, Williams J, Calais J. Total-body ⁶⁸Ga-PSMA-11 PET/CT for bone metastasis detection in prostate cancer patients: potential impact on bone scan guidelines. J Nucl Med. 2020;61(3):405-411. doi:10.2967/jnumed.119.230318 3. Hope TA, Aggarwal R, Chee B, et al. Impact of ⁶⁸Ga-PSMA-11 PET on management in patients with biochemically recurrent prostate cancer. J Nucl Med. 2017;58(12):1956-1961. doi:10.2967/jnumed.117.192476 4. Tsourlakis MC, Klein F, Kluth M, et al. PSMA expression is highly homogenous in primary prostate cancer. Appl Immunohistochem Mol Morphol. 2015;23(6):449-455. doi:10.1097/PAI.0000000000000110 5. Minner S, Wittmer C, Graefen M, et al. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate. 2011;71(3):281-288. doi:10.1002/pros.21241 6. Pluvicto. Prescribing information. Novartis Pharmaceuticals Corp. 7. Hofman MS, Violet J, Hicks RJ, et al. [¹⁷⁷Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19(6):825-833. doi:10.1016/S1470-2045(18)30198-0 8. Vlachostergios PJ, Niaz MJ, Sun M, et al. Prostate-specific membrane antigen uptake and survival in metastatic castration-resistant prostate cancer. Front Oncol. 2021;11:630589. doi:10.3389/fonc.2021.630589 9. Maffey-Steffan J, Scarpa L, Svirydenka A, et al. The ⁶⁸Ga/¹⁷⁷Lu-theragnostic concept in PSMA targeting of metastatic castration–resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up. Eur J Nucl Med Mol Imaging. 2020;47(3):695-712. doi:10.1007/s00259-019-04583-2 10. Woythal N, Arsenic R, Kempkensteffen C, et al. Immunohistochemical validation of PSMA expression measured by ⁶⁸Ga-PSMA PET/CT in primary prostate cancer. J Nucl Med. 2018;59(2):238-243. doi:10.2967/jnumed.117.195172 11. Baum RP, Kulkarni HR, Schuchardt C, et al. ¹⁷⁷Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med. 2016;57(7):1006-1013. doi:10.2967/jnumed.115.168443 12. Sartor O, de Bono J, Chi KN, et al; VISION Investigators. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. Published online June 23, 2021. 2021;385(12):1091-1103. doi:10.1056/NEJMoa2107322.

Why Scan for PSMA?

More than 80% of patients with prostate cancer are PSMA+, making PSMA an ideal diagnostic and therapeutic target^1-5

Learn about PSMA PET/CT scanning as a diagnostic tool

Scanning to Determine PSMA Status

PSMA scanning helps you see and target PSMA+ mCRPC^7-9

Scan to determine PSMA status. Knowing your patient who has received an ARPI and taxane is PSMA+ enables you to offer a PSMA-targeted RLT.⁶

Patients in Your Practice Who May Benefit From PLUVICTO

Consider a PSMA PET/CT for patients in your practice with mCRPC^6,12

What is your next step for patients like Stan?

What is your next step for patients like Maurice?

What is your next step for patients like José?

What is your next step for patients like Elliot?

Important Safety Information

Indication

Why Scan for PSMA?

More than 80% of patients with prostate cancer are PSMA+, making PSMA an ideal diagnostic and therapeutic target1-5

Learn about PSMA PET/CT scanning as a diagnostic tool

Scanning to Determine PSMA Status

PSMA scanning helps you see and target PSMA+ mCRPC7-9

Scan to determine PSMA status. Knowing your patient who has received an ARPI and taxane is PSMA+ enables you to offer a PSMA-targeted RLT.6

Patients in Your Practice Who May Benefit From PLUVICTO

Consider a PSMA PET/CT for patients in your practice with mCRPC6,12

What is your next step for patients like Stan?

What is your next step for patients like Maurice?

What is your next step for patients like José?

What is your next step for patients like Elliot?

More than 80% of patients with prostate cancer are PSMA+, making PSMA an ideal diagnostic and therapeutic target^1-5

PSMA scanning helps you see and target PSMA+ mCRPC^7-9

Scan to determine PSMA status. Knowing your patient who has received an ARPI and taxane is PSMA+ enables you to offer a PSMA-targeted RLT.⁶

Consider a PSMA PET/CT for patients in your practice with mCRPC^6,12